<?xml version="1.0" encoding="UTF-8" ?><!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
	"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" >
<html><head><title>Side-by-side differences</title><link rel="stylesheet" type="text/css" href="/archive/history.css" /><link rel="stylesheet" type="text/css" href="/archive/sdiff.css" /><script type="text/javascript" src="/archive/common.js"></script><script type="text/javascript" src="/archive/sdiff.js"></script><style>table.sdiff div.sdl0 { margin-left: 0em; }
table.sdiff div.sdl1 { margin-left: 2em; }
table.sdiff div.sdl2 { margin-left: 4em; }
table.sdiff div.sdl3 { margin-left: 6em; }
table.sdiff div.sdl4 { margin-left: 8em; }
table.sdiff div.sdl5 { margin-left: 10em; }
table.sdiff div.sdl6 { margin-left: 12em; }
table.sdiff div.sdl7 { margin-left: 14em; }
table.sdiff div.sdl8 { margin-left: 16em; }
table.sdiff div.sdl9 { margin-left: 18em; }
table.sdiff div.sdl10 { margin-left: 20em; }
table.sdiff div.sdl11 { margin-left: 22em; }
table.sdiff div.sdl12 { margin-left: 24em; }
table.sdiff div.sdl13 { margin-left: 26em; }
table.sdiff div.sdl14 { margin-left: 28em; }
table.sdiff div.sdl15 { margin-left: 30em; }
table.sdiff div.sdl16 { margin-left: 32em; }
table.sdiff div.sdl17 { margin-left: 34em; }
table.sdiff div.sdl18 { margin-left: 36em; }
table.sdiff div.sdl19 { margin-left: 38em; }
</style></head><body class="sdiff">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="sdiff-links" class="navLinks" /><div id="navLinks" class="navLinks"><a href="/archive/NCT02075515">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT02075515">&#8593; Current version of this study</a></div><form><div id="sdiff-js-menu" style="display: none"><div><input type="checkbox" id="sdiff-HideUnch-cb" name="sdiff-HideUnch" value="true" onclick="SDiffUpdateHideUnch(&#39;sdiff-HideUnch-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideUnch(&#39;sdiff-HideUnch-cb&#39;)"> Hide unchanged portions (except top/bottom lines)</span></div><div><input type="checkbox" id="sdiff-HideNonMain-cb" name="sdiff-HideNonMain" value="true" onclick="SDiffUpdateHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)"> Hide non-essential portions (contact info, locations, etc.)</span></div><div style="display:none"><input type="checkbox" id="sdiff-HideKey-cb" name="sdiff-HideKey" value="true" onclick="SDiffUpdateHideKey(&#39;sdiff-HideKey-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)"> Hide key</span></div></div><h1>Changes to NCT02075515 on 2014_03_28</h1><div id="sdiff-key"><div id="sdiff-key-mb"><img id="sdiff-key-minmax" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)" src="/archive/minmax.gif" alt="[+/-]" width="16" height="16" style="display:none" /><h2>Key</h2></div><img id="sdiff-key-img" src="/archive/sdiff-key.gif" alt="Key" /></div><div class="sdiff-changedesc"><em>Type of info changed: </em>Misc.</div><div class="sdiff-view" id="sdiff-full" style="display: none"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><a href="/archive/NCT02075515/2014_03_07/changes" title="Show changes from prior version to this one"><img src="/archive/prev.gif" alt="[Previous]" width="23" height="19" /></a></div><h2>Before</h2><h3><a href="/archive/NCT02075515/2014_03_07">(Updated 2014_03_07)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT02075515/2014_04_11/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT02075515/2014_03_28">(Updated 2014_03_28)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-f1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-f0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0A-cdiv" class="sdiff-collapsed" title="The middle 242 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  GSK</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  GlaxoSmithKline</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  117177</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
<div class="sdl4">  2013-000373-76</div>
<div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl3 sds">&lt;id_type&gt;</div>
<div class="sdl4">  EudraCT Number</div>
<div class="sdl3 sdz">&lt;/id_type&gt;</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT02075515</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;is_section_801&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_section_801&gt;</div>
<div class="sdl1 sds">&lt;delayed_posting&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/delayed_posting&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals&amp;apos; Herpes Zoster (HZ) Vaccine GSK1437173A in Adults &amp;#8805; 50 Years of Age</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Consistency, Immunogenicity and Safety Study of GSK Biologicals&amp;apos; Herpes Zoster Vaccine GSK1437173A in Adults &amp;#8805; 50 Years of Age</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  GlaxoSmithKline</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  Belgium: Federal Agency for Medicines and Health Products, FAMHP</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  Panama: Ministerio de Salud de Panama</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Not yet recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2014-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2014-07</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;last_follow_up_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2016-02</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2015-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 3</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Prevention</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Double Blind (Subject, Caregiver, Investigator)</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Parallel Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  3</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Anti-gE humoral immunogenicity</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  At Month 3</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Anti-gE antibody concentrations, as determined by enzyme-linked immunosorbent assay (ELISA)</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Anti-gE humoral immunogenicity</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  At Month 0 and Month 3</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Anti-gE antibody concentrations, as determined by ELISA</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Anti-gE humoral immunogenicity</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  At Month 3</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Vaccine response for anti-gE humoral immunogenicity, as determined by ELISA, at Month 3</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of solicited local and general symptoms</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  Within 7 days (Days 0-6) after each vaccination</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of unsolicited symptoms</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  During 30 days (Days 0-29) after each vaccination</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of Serious Adverse Events (SAEs)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  From first vaccination up to 30 days post last vaccination (Month 0-Month 3)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of Serious Adverse Events (SAEs)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  During the period starting after 30 days post last vaccination until study end (Month 4 -Month 14)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of AEs of specific interest</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  From first vaccination up to 30 days post last vaccination (Month 0-Month 3)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of AEs of specific interest</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  During the period starting after 30 days post last vaccination until study end (Month 4 -Month 14)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
</div><div class="sdl1">&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0B-cdiv" class="sdiff-collapsed" title="The middle 242 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  GSK</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  GlaxoSmithKline</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  117177</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
<div class="sdl4">  2013-000373-76</div>
<div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl3 sds">&lt;id_type&gt;</div>
<div class="sdl4">  EudraCT Number</div>
<div class="sdl3 sdz">&lt;/id_type&gt;</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT02075515</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;is_section_801&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_section_801&gt;</div>
<div class="sdl1 sds">&lt;delayed_posting&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/delayed_posting&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals&amp;apos; Herpes Zoster (HZ) Vaccine GSK1437173A in Adults &amp;#8805; 50 Years of Age</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Consistency, Immunogenicity and Safety Study of GSK Biologicals&amp;apos; Herpes Zoster Vaccine GSK1437173A in Adults &amp;#8805; 50 Years of Age</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  GlaxoSmithKline</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  Belgium: Federal Agency for Medicines and Health Products, FAMHP</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  Panama: Ministerio de Salud de Panama</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Not yet recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2014-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2014-07</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;last_follow_up_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2016-02</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2015-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 3</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Prevention</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Double Blind (Subject, Caregiver, Investigator)</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Parallel Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  3</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Anti-gE humoral immunogenicity</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  At Month 3</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Anti-gE antibody concentrations, as determined by enzyme-linked immunosorbent assay (ELISA)</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Anti-gE humoral immunogenicity</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  At Month 0 and Month 3</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Anti-gE antibody concentrations, as determined by ELISA</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Anti-gE humoral immunogenicity</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  At Month 3</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Vaccine response for anti-gE humoral immunogenicity, as determined by ELISA, at Month 3</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of solicited local and general symptoms</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  Within 7 days (Days 0-6) after each vaccination</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of unsolicited symptoms</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  During 30 days (Days 0-29) after each vaccination</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of Serious Adverse Events (SAEs)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  From first vaccination up to 30 days post last vaccination (Month 0-Month 3)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of Serious Adverse Events (SAEs)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  During the period starting after 30 days post last vaccination until study end (Month 4 -Month 14)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of AEs of specific interest</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  From first vaccination up to 30 days post last vaccination (Month 0-Month 3)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of AEs of specific interest</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  During the period starting after 30 days post last vaccination until study end (Month 4 -Month 14)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
</div><div class="sdl1">&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">450</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">651</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><img id="sdiff-collapse-f245A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f245&#39;)" style="display:none" /><img id="sdiff-collapse-f245A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f245&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div id="sdiff-collapse-f245A-cdiv" class="sdiff-collapsed" title="The middle 161 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f245&#39;)" style="display:none"></div><div id="sdiff-collapse-f245A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Herpes Zoster</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot A</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Subjects will receive Lot A of the HZ/su vaccine at 0 and 2 months.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot B</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Subjects will receive Lot B of the HZ/su vaccine at 0 and 2 months.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot C</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Subjects will receive Lot C of the HZ/su vaccine at 0 and 2 months.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Biological/Vaccine</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Herpes Zoster vaccine (GSK 1437173A)</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  2 doses administered intramuscularly in deltoid region of non-dominant arm.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot B</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot C</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot A</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  HZ/su vaccine</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  &amp;#8226;  Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.</div>
<div class="sdl4">  &amp;#8226;  A male or female aged 50 years or older at the time of the first vaccination.</div>
<div class="sdl4">  &amp;#8226;  Written informed consent obtained from the subject.</div>
<div class="sdl4">  &amp;#8226;  Female subjects of non-childbearing potential may be enrolled in the study. </div>
<div class="sdl4">     -  Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.</div>
<div class="sdl4">  &amp;#8226;  Female subjects of childbearing potential may be enrolled in the study, if the subject:</div>
<div class="sdl4">     -  has practiced adequate contraception for 30 days prior to vaccination, and</div>
<div class="sdl4">     -  has a negative pregnancy test on the day of vaccination, and</div>
<div class="sdl4">     -  has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series. </div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  &amp;#8226;  Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.</div>
<div class="sdl4">  &amp;#8226;  Chronic administration  of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. A prednisone dose of &amp;lt; 20 mg/day is allowed. Inhaled, topical and intra-articular corticosteroids are allowed.</div>
<div class="sdl4">  &amp;#8226;  Administration or planned administration of a live vaccine in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine. </div>
<div class="sdl4">  &amp;#8226;  Administration of long-acting immune-modifying drugs within six months prior to the first vaccine dose or expected administration at any time during the study period.</div>
<div class="sdl4">  &amp;#8226;  Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.</div>
<div class="sdl4">  &amp;#8226;  Previous vaccination against HZ or varicella.</div>
<div class="sdl4">  &amp;#8226;  Planned administration during the study of an HZ or varicella vaccine other than the study vaccine.</div>
<div class="sdl4">  &amp;#8226;  History of HZ.</div>
<div class="sdl4">  &amp;#8226;  Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy.</div>
<div class="sdl4">  &amp;#8226;  History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.</div>
<div class="sdl4">  &amp;#8226;  Acute disease and/or fever at the time of enrollment. </div>
<div class="sdl4">     -  Fever is defined as temperature &amp;#8805; 37.5&amp;#176;C (99.5&amp;#176;F) on oral, axillary or tympanic route, or &amp;#8805; 38.0&amp;#176;C (100.4&amp;#176;F) on rectal route. The preferred route for recording temperature in this study will be oral.</div>
<div class="sdl4">     -  Subjects with a minor illness  without fever may be enrolled at the discretion of the investigator. </div>
<div class="sdl4">  &amp;#8226;  Administration of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine or planned administration during the study period.</div>
<div class="sdl4">  &amp;#8226;  Pregnant or lactating females.</div>
<div class="sdl4">  &amp;#8226;  Females planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential) before Month 4. </div>
<div class="sdl4">  &amp;#8226;  Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.</div>
<div class="sdl4">  &amp;#8226;  Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.</div>
<div class="sdl4">  &amp;#8226;  Any condition which, in the judgment of the investigator would make intramuscular injection unsafe.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  50 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Study Director</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  GSK Clinical Trials</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  GlaxoSmithKline</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;contact&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  US GSK Clinical Trials Call Center</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;phone&gt;</div>
<div class="sdl3">  877-379-3718</div>
<div class="sdl2 sdz">&lt;/phone&gt;</div>
<div class="sdl2 sds">&lt;phone_ext&gt;</div>
<div class="sdl2 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl2 sds">&lt;email&gt;</div>
<div class="sdl3">  GSKClinicalSupportHD@gsk.com</div>
<div class="sdl2 sdz">&lt;/email&gt;</div>
<div class="sdl1 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Safety</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Zoster</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Immunogenicity</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Adults</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Consistency</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2014-02-27</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f245B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f245&#39;)" style="display:none" /><img id="sdiff-collapse-f245B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f245&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div id="sdiff-collapse-f245B-cdiv" class="sdiff-collapsed" title="The middle 161 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f245&#39;)" style="display:none"></div><div id="sdiff-collapse-f245B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Herpes Zoster</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot A</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Subjects will receive Lot A of the HZ/su vaccine at 0 and 2 months.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot B</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Subjects will receive Lot B of the HZ/su vaccine at 0 and 2 months.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot C</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Subjects will receive Lot C of the HZ/su vaccine at 0 and 2 months.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Biological/Vaccine</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Herpes Zoster vaccine (GSK 1437173A)</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  2 doses administered intramuscularly in deltoid region of non-dominant arm.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot B</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot C</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot A</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  HZ/su vaccine</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  &amp;#8226;  Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.</div>
<div class="sdl4">  &amp;#8226;  A male or female aged 50 years or older at the time of the first vaccination.</div>
<div class="sdl4">  &amp;#8226;  Written informed consent obtained from the subject.</div>
<div class="sdl4">  &amp;#8226;  Female subjects of non-childbearing potential may be enrolled in the study. </div>
<div class="sdl4">     -  Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.</div>
<div class="sdl4">  &amp;#8226;  Female subjects of childbearing potential may be enrolled in the study, if the subject:</div>
<div class="sdl4">     -  has practiced adequate contraception for 30 days prior to vaccination, and</div>
<div class="sdl4">     -  has a negative pregnancy test on the day of vaccination, and</div>
<div class="sdl4">     -  has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series. </div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  &amp;#8226;  Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.</div>
<div class="sdl4">  &amp;#8226;  Chronic administration  of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. A prednisone dose of &amp;lt; 20 mg/day is allowed. Inhaled, topical and intra-articular corticosteroids are allowed.</div>
<div class="sdl4">  &amp;#8226;  Administration or planned administration of a live vaccine in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine. </div>
<div class="sdl4">  &amp;#8226;  Administration of long-acting immune-modifying drugs within six months prior to the first vaccine dose or expected administration at any time during the study period.</div>
<div class="sdl4">  &amp;#8226;  Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.</div>
<div class="sdl4">  &amp;#8226;  Previous vaccination against HZ or varicella.</div>
<div class="sdl4">  &amp;#8226;  Planned administration during the study of an HZ or varicella vaccine other than the study vaccine.</div>
<div class="sdl4">  &amp;#8226;  History of HZ.</div>
<div class="sdl4">  &amp;#8226;  Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy.</div>
<div class="sdl4">  &amp;#8226;  History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.</div>
<div class="sdl4">  &amp;#8226;  Acute disease and/or fever at the time of enrollment. </div>
<div class="sdl4">     -  Fever is defined as temperature &amp;#8805; 37.5&amp;#176;C (99.5&amp;#176;F) on oral, axillary or tympanic route, or &amp;#8805; 38.0&amp;#176;C (100.4&amp;#176;F) on rectal route. The preferred route for recording temperature in this study will be oral.</div>
<div class="sdl4">     -  Subjects with a minor illness  without fever may be enrolled at the discretion of the investigator. </div>
<div class="sdl4">  &amp;#8226;  Administration of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine or planned administration during the study period.</div>
<div class="sdl4">  &amp;#8226;  Pregnant or lactating females.</div>
<div class="sdl4">  &amp;#8226;  Females planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential) before Month 4. </div>
<div class="sdl4">  &amp;#8226;  Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.</div>
<div class="sdl4">  &amp;#8226;  Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.</div>
<div class="sdl4">  &amp;#8226;  Any condition which, in the judgment of the investigator would make intramuscular injection unsafe.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  50 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Study Director</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  GSK Clinical Trials</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  GlaxoSmithKline</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;contact&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  US GSK Clinical Trials Call Center</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;phone&gt;</div>
<div class="sdl3">  877-379-3718</div>
<div class="sdl2 sdz">&lt;/phone&gt;</div>
<div class="sdl2 sds">&lt;phone_ext&gt;</div>
<div class="sdl2 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl2 sds">&lt;email&gt;</div>
<div class="sdl3">  GSKClinicalSupportHD@gsk.com</div>
<div class="sdl2 sdz">&lt;/email&gt;</div>
<div class="sdl1 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Safety</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Zoster</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Immunogenicity</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Adults</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Consistency</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2014-02-27</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">2014-03-06</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">2014-03-27</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><img id="sdiff-collapse-f409A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f409&#39;)" style="display:none" /><img id="sdiff-collapse-f409A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f409&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-f409A-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f409&#39;)" style="display:none"></div><div id="sdiff-collapse-f409A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f409B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f409&#39;)" style="display:none" /><img id="sdiff-collapse-f409B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f409&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-f409B-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f409&#39;)" style="display:none"></div><div id="sdiff-collapse-f409B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div><div class="sdiff-view" id="sdiff-main" style="display: block"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><a href="/archive/NCT02075515/2014_03_07/changes" title="Show changes from prior version to this one"><img src="/archive/prev.gif" alt="[Previous]" width="23" height="19" /></a></div><h2>Before</h2><h3><a href="/archive/NCT02075515/2014_03_07">(Updated 2014_03_07)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT02075515/2014_04_11/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT02075515/2014_03_28">(Updated 2014_03_28)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-m1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-m0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0A-cdiv" class="sdiff-collapsed" title="The middle 242 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  GSK</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  GlaxoSmithKline</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  117177</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
<div class="sdl4">  2013-000373-76</div>
<div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl3 sds">&lt;id_type&gt;</div>
<div class="sdl4">  EudraCT Number</div>
<div class="sdl3 sdz">&lt;/id_type&gt;</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT02075515</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;is_section_801&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_section_801&gt;</div>
<div class="sdl1 sds">&lt;delayed_posting&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/delayed_posting&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals&amp;apos; Herpes Zoster (HZ) Vaccine GSK1437173A in Adults &amp;#8805; 50 Years of Age</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Consistency, Immunogenicity and Safety Study of GSK Biologicals&amp;apos; Herpes Zoster Vaccine GSK1437173A in Adults &amp;#8805; 50 Years of Age</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  GlaxoSmithKline</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  Belgium: Federal Agency for Medicines and Health Products, FAMHP</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  Panama: Ministerio de Salud de Panama</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Not yet recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2014-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2014-07</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;last_follow_up_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2016-02</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2015-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 3</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Prevention</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Double Blind (Subject, Caregiver, Investigator)</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Parallel Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  3</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Anti-gE humoral immunogenicity</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  At Month 3</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Anti-gE antibody concentrations, as determined by enzyme-linked immunosorbent assay (ELISA)</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Anti-gE humoral immunogenicity</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  At Month 0 and Month 3</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Anti-gE antibody concentrations, as determined by ELISA</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Anti-gE humoral immunogenicity</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  At Month 3</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Vaccine response for anti-gE humoral immunogenicity, as determined by ELISA, at Month 3</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of solicited local and general symptoms</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  Within 7 days (Days 0-6) after each vaccination</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of unsolicited symptoms</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  During 30 days (Days 0-29) after each vaccination</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of Serious Adverse Events (SAEs)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  From first vaccination up to 30 days post last vaccination (Month 0-Month 3)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of Serious Adverse Events (SAEs)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  During the period starting after 30 days post last vaccination until study end (Month 4 -Month 14)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of AEs of specific interest</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  From first vaccination up to 30 days post last vaccination (Month 0-Month 3)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of AEs of specific interest</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  During the period starting after 30 days post last vaccination until study end (Month 4 -Month 14)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
</div><div class="sdl1">&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0B-cdiv" class="sdiff-collapsed" title="The middle 242 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  GSK</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  GlaxoSmithKline</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  117177</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3 sds">&lt;id&gt;</div>
<div class="sdl4">  2013-000373-76</div>
<div class="sdl3 sdz">&lt;/id&gt;</div>
<div class="sdl3 sds">&lt;id_type&gt;</div>
<div class="sdl4">  EudraCT Number</div>
<div class="sdl3 sdz">&lt;/id_type&gt;</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT02075515</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;is_section_801&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_section_801&gt;</div>
<div class="sdl1 sds">&lt;delayed_posting&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/delayed_posting&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals&amp;apos; Herpes Zoster (HZ) Vaccine GSK1437173A in Adults &amp;#8805; 50 Years of Age</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Consistency, Immunogenicity and Safety Study of GSK Biologicals&amp;apos; Herpes Zoster Vaccine GSK1437173A in Adults &amp;#8805; 50 Years of Age</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  GlaxoSmithKline</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  Belgium: Federal Agency for Medicines and Health Products, FAMHP</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  Panama: Ministerio de Salud de Panama</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Not yet recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2014-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2014-07</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;last_follow_up_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2016-02</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2015-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 3</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Prevention</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Double Blind (Subject, Caregiver, Investigator)</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Parallel Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  3</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Anti-gE humoral immunogenicity</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  At Month 3</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Anti-gE antibody concentrations, as determined by enzyme-linked immunosorbent assay (ELISA)</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Anti-gE humoral immunogenicity</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  At Month 0 and Month 3</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Anti-gE antibody concentrations, as determined by ELISA</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Anti-gE humoral immunogenicity</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  At Month 3</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Vaccine response for anti-gE humoral immunogenicity, as determined by ELISA, at Month 3</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of solicited local and general symptoms</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  Within 7 days (Days 0-6) after each vaccination</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of unsolicited symptoms</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  During 30 days (Days 0-29) after each vaccination</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of Serious Adverse Events (SAEs)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  From first vaccination up to 30 days post last vaccination (Month 0-Month 3)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of Serious Adverse Events (SAEs)</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  During the period starting after 30 days post last vaccination until study end (Month 4 -Month 14)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of AEs of specific interest</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  From first vaccination up to 30 days post last vaccination (Month 0-Month 3)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Occurrence of AEs of specific interest</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  During the period starting after 30 days post last vaccination until study end (Month 4 -Month 14)</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
</div><div class="sdl1">&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">450</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">651</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><img id="sdiff-collapse-m245A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m245&#39;)" style="display:none" /><img id="sdiff-collapse-m245A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m245&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div id="sdiff-collapse-m245A-cdiv" class="sdiff-collapsed" title="The middle 148 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m245&#39;)" style="display:none"></div><div id="sdiff-collapse-m245A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Herpes Zoster</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot A</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Subjects will receive Lot A of the HZ/su vaccine at 0 and 2 months.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot B</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Subjects will receive Lot B of the HZ/su vaccine at 0 and 2 months.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot C</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Subjects will receive Lot C of the HZ/su vaccine at 0 and 2 months.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Biological/Vaccine</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Herpes Zoster vaccine (GSK 1437173A)</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  2 doses administered intramuscularly in deltoid region of non-dominant arm.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot B</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot C</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot A</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  HZ/su vaccine</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  &amp;#8226;  Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.</div>
<div class="sdl4">  &amp;#8226;  A male or female aged 50 years or older at the time of the first vaccination.</div>
<div class="sdl4">  &amp;#8226;  Written informed consent obtained from the subject.</div>
<div class="sdl4">  &amp;#8226;  Female subjects of non-childbearing potential may be enrolled in the study. </div>
<div class="sdl4">     -  Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.</div>
<div class="sdl4">  &amp;#8226;  Female subjects of childbearing potential may be enrolled in the study, if the subject:</div>
<div class="sdl4">     -  has practiced adequate contraception for 30 days prior to vaccination, and</div>
<div class="sdl4">     -  has a negative pregnancy test on the day of vaccination, and</div>
<div class="sdl4">     -  has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series. </div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  &amp;#8226;  Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.</div>
<div class="sdl4">  &amp;#8226;  Chronic administration  of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. A prednisone dose of &amp;lt; 20 mg/day is allowed. Inhaled, topical and intra-articular corticosteroids are allowed.</div>
<div class="sdl4">  &amp;#8226;  Administration or planned administration of a live vaccine in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine. </div>
<div class="sdl4">  &amp;#8226;  Administration of long-acting immune-modifying drugs within six months prior to the first vaccine dose or expected administration at any time during the study period.</div>
<div class="sdl4">  &amp;#8226;  Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.</div>
<div class="sdl4">  &amp;#8226;  Previous vaccination against HZ or varicella.</div>
<div class="sdl4">  &amp;#8226;  Planned administration during the study of an HZ or varicella vaccine other than the study vaccine.</div>
<div class="sdl4">  &amp;#8226;  History of HZ.</div>
<div class="sdl4">  &amp;#8226;  Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy.</div>
<div class="sdl4">  &amp;#8226;  History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.</div>
<div class="sdl4">  &amp;#8226;  Acute disease and/or fever at the time of enrollment. </div>
<div class="sdl4">     -  Fever is defined as temperature &amp;#8805; 37.5&amp;#176;C (99.5&amp;#176;F) on oral, axillary or tympanic route, or &amp;#8805; 38.0&amp;#176;C (100.4&amp;#176;F) on rectal route. The preferred route for recording temperature in this study will be oral.</div>
<div class="sdl4">     -  Subjects with a minor illness  without fever may be enrolled at the discretion of the investigator. </div>
<div class="sdl4">  &amp;#8226;  Administration of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine or planned administration during the study period.</div>
<div class="sdl4">  &amp;#8226;  Pregnant or lactating females.</div>
<div class="sdl4">  &amp;#8226;  Females planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential) before Month 4. </div>
<div class="sdl4">  &amp;#8226;  Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.</div>
<div class="sdl4">  &amp;#8226;  Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.</div>
<div class="sdl4">  &amp;#8226;  Any condition which, in the judgment of the investigator would make intramuscular injection unsafe.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  50 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Study Director</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  GSK Clinical Trials</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  GlaxoSmithKline</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Safety</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Zoster</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Immunogenicity</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Adults</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Consistency</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2014-02-27</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m245B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m245&#39;)" style="display:none" /><img id="sdiff-collapse-m245B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m245&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div id="sdiff-collapse-m245B-cdiv" class="sdiff-collapsed" title="The middle 148 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m245&#39;)" style="display:none"></div><div id="sdiff-collapse-m245B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Herpes Zoster</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot A</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Subjects will receive Lot A of the HZ/su vaccine at 0 and 2 months.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot B</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Subjects will receive Lot B of the HZ/su vaccine at 0 and 2 months.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot C</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Subjects will receive Lot C of the HZ/su vaccine at 0 and 2 months.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Biological/Vaccine</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Herpes Zoster vaccine (GSK 1437173A)</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  2 doses administered intramuscularly in deltoid region of non-dominant arm.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot B</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot C</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  HZ/su Lot A</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  HZ/su vaccine</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  &amp;#8226;  Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.</div>
<div class="sdl4">  &amp;#8226;  A male or female aged 50 years or older at the time of the first vaccination.</div>
<div class="sdl4">  &amp;#8226;  Written informed consent obtained from the subject.</div>
<div class="sdl4">  &amp;#8226;  Female subjects of non-childbearing potential may be enrolled in the study. </div>
<div class="sdl4">     -  Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.</div>
<div class="sdl4">  &amp;#8226;  Female subjects of childbearing potential may be enrolled in the study, if the subject:</div>
<div class="sdl4">     -  has practiced adequate contraception for 30 days prior to vaccination, and</div>
<div class="sdl4">     -  has a negative pregnancy test on the day of vaccination, and</div>
<div class="sdl4">     -  has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series. </div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  &amp;#8226;  Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.</div>
<div class="sdl4">  &amp;#8226;  Chronic administration  of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. A prednisone dose of &amp;lt; 20 mg/day is allowed. Inhaled, topical and intra-articular corticosteroids are allowed.</div>
<div class="sdl4">  &amp;#8226;  Administration or planned administration of a live vaccine in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine. </div>
<div class="sdl4">  &amp;#8226;  Administration of long-acting immune-modifying drugs within six months prior to the first vaccine dose or expected administration at any time during the study period.</div>
<div class="sdl4">  &amp;#8226;  Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.</div>
<div class="sdl4">  &amp;#8226;  Previous vaccination against HZ or varicella.</div>
<div class="sdl4">  &amp;#8226;  Planned administration during the study of an HZ or varicella vaccine other than the study vaccine.</div>
<div class="sdl4">  &amp;#8226;  History of HZ.</div>
<div class="sdl4">  &amp;#8226;  Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy.</div>
<div class="sdl4">  &amp;#8226;  History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.</div>
<div class="sdl4">  &amp;#8226;  Acute disease and/or fever at the time of enrollment. </div>
<div class="sdl4">     -  Fever is defined as temperature &amp;#8805; 37.5&amp;#176;C (99.5&amp;#176;F) on oral, axillary or tympanic route, or &amp;#8805; 38.0&amp;#176;C (100.4&amp;#176;F) on rectal route. The preferred route for recording temperature in this study will be oral.</div>
<div class="sdl4">     -  Subjects with a minor illness  without fever may be enrolled at the discretion of the investigator. </div>
<div class="sdl4">  &amp;#8226;  Administration of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine or planned administration during the study period.</div>
<div class="sdl4">  &amp;#8226;  Pregnant or lactating females.</div>
<div class="sdl4">  &amp;#8226;  Females planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential) before Month 4. </div>
<div class="sdl4">  &amp;#8226;  Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.</div>
<div class="sdl4">  &amp;#8226;  Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.</div>
<div class="sdl4">  &amp;#8226;  Any condition which, in the judgment of the investigator would make intramuscular injection unsafe.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  50 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Study Director</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  GSK Clinical Trials</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  GlaxoSmithKline</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Safety</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Zoster</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Immunogenicity</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Adults</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Consistency</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2014-02-27</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">2014-03-06</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">2014-03-27</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><img id="sdiff-collapse-m396A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m396&#39;)" style="display:none" /><img id="sdiff-collapse-m396A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m396&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-m396A-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m396&#39;)" style="display:none"></div><div id="sdiff-collapse-m396A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m396B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m396&#39;)" style="display:none" /><img id="sdiff-collapse-m396B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m396&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-m396B-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m396&#39;)" style="display:none"></div><div id="sdiff-collapse-m396B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div></form><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div><script>
SDiffDeclareUnchCRID('sdiff-collapse-f0');
SDiffDeclareUnchCRID('sdiff-collapse-f245');
SDiffDeclareUnchCRID('sdiff-collapse-f409');
SDiffDeclareUnchCRID('sdiff-collapse-m0');
SDiffDeclareUnchCRID('sdiff-collapse-m245');
SDiffDeclareUnchCRID('sdiff-collapse-m396');
SDiffInit();
</script></body></html>